Anti-programmed cell death protein 1 (PD-1) agents are indicated for the treatment of advanced skin cancer with a high tumor mutational burden (TMB) in Japan, but neither drug is necessarily effective for EMPD. Here, PDCD1 is linked to skin neoplasm.